1-7 of 7
Paul Moore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Dilan Anil Patel, Ezhilarasi Chendamarai, Julie K. Ritchey, Michael P. Rettig, Leah Gehrs, Paul Moore, Ralph F. Alderson, Ezio Bonvini, Matthew Christopher, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 8795–8796.
https://doi.org/10.1182/blood-2022-156943
Published: 2022
Journal Articles

Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia

Ralph F. Alderson, Ling Huang, Xiaoyu Zhang, Haiquan Li, Thomas Kaufman, Gundo Diedrich, Paul Moore, Ezio Bonvini
Journal: Blood
Blood (2021) 138 (Supplement 1): 1165.
https://doi.org/10.1182/blood-2021-153192
Published: 2021
Journal Articles

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, MD, Adam S. Asch, MD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Andrew Weickhardt, MBBS(Hons) FRACP DMedSc, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, MD PhD, Halyna Pylypenko, MD, Shakeela Bahadur, MD, Susanna Ulahannan, MD MMed, Janine Koucheki, Jichao Sun, PhD, Hua Li, Francine Chen, MD, Xiaoyu Zhang, John Muth, MS, Patrick Kaminker, PhD, Paul Moore, PhD, Bradley James Sumrow, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-139868
Published: 2020
Journal Articles

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Ezio Bonvini, MD, Ross La Motte-Mohs, PhD, Ling Huang, Chia-Ying Kao Lam, PhD, Thomas Kaufman, Liqin Liu, PhD, Ralph F. Alderson, PhD, Kurt Stahl, Jennifer G. Brown, PhD, Hua Li, Sharad Sharma, PhD, James Tamura, PhD, Syd Johnson, PhD, Paul Moore, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5230.
https://doi.org/10.1182/blood-2018-99-116264
Published: 2018
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017
Journal Articles

MGD011, Humanized CD19 x CD3 DART ® Protein with Enhanced Pharmacokinetic Properties, Demonstrates Potent T-Cell Mediated Anti-Tumor Activity in Preclinical Models and Durable B-Cell Depletion in Cynomolgus Monkeys Following Once-a-Week Dosing

Liqin Liu, PhD, Annie Lam, PhD, Ralph Alderson, PhD, Yinhua Yang, MD, Hua Li, M.S., Vatana Long, M.S., Sergey Gorlatov, PhD, Steve Burke, B.S., Valentina Ciccarone, PhD, Jeffrey Nordstrom, PhD, Syd Johnson, PhD, Paul Moore, PhD, Ezio Bonvini, MD
Journal: Blood
Blood (2014) 124 (21): 1775.
https://doi.org/10.1182/blood.V124.21.1775.1775
Published: 2014
Journal Articles

CCL16 activates an angiogenic program in vascular endothelial cells

Marina Strasly, Gabriella Doronzo, Paola Capello, Donatella Valdembri, Marco Arese, Stefania Mitola, Paul Moore, Giulio Alessandri, Mirella Giovarelli, Federico Bussolino
Journal: Blood
Blood (2004) 103 (1): 40–49.
https://doi.org/10.1182/blood-2003-05-1387
Published: 2004